In the NMDA-induced AD animal model, administration of either ATROSAB, a TNFR1 antagonist, or EHD2-SCTNFR2, a TNFR2 agonist, prevented neurodegeneration and mediated neuroprotection (125). This evidence concerns the gene TNFRSF1A and Alzheimer disease.